Effect of Statin Intake on FVIII Levels and Bleeding Outcomes in Hypercholesterolemic Patients with Hemophilia A

Patients with hemophilia A are not protected from atherosclerosis, despite their condition of hypocoagulablity, and nowadays that life expectancy of hemophiliacs approaches that of non-hemophilic peers, cardiovascular (CV) disease represents a significant cause of morbidity and mortality also in this patient population [1]. However, since the use of either antiplatelet or anticoagulant agents associates with a relevant bleeding risk in these patients, the control of CV-risk factors, and in particular of hypercholesterolemia, becomes pivotal for primary and secondary CV prophylaxis.